Feedback / Questions
IO-108 - Immune-Onc Therap
https://www.businesswire.com/news/home/20250227540556/en/Immune-Onc-Therapeutics-Announces-First-Patient-Dosed-with-IO-108-in-a-Randomized-Global-Phase-1b2-Study-of-First-Line-Treatment-of-Advanced-Liver-Cancer-in-Clinical-Collaboration-with-Roche
Feb 27, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next